A Phase 3 interventional study of CTP-543 matching placebo and CTP-543 in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 72 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 5 in phase 3, and was the 5th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:
Sun Pharma Japan Limited · Sites in Japan
Ages 18–65
Sun Pharmaceutical Industries, Inc. · Sites in United States, Canada
Ages 12–17
By country, each count listing its studies:
Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2017; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 706 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 336 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Concert Pharmaceuticals, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited: 2 open now, 3 under way, 3 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 5 in phase 3, and was the 5th registered.
Sun Pharmaceutical Industries Limited’s Alopecia Areata studies by the year they started, since 2017.
1 of the studies testing deuruxolitinib in Alopecia Areata that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 10 in Alopecia Areata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
Drug: CTP-543 matching placebo
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
Drug: CTP-543
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Drug: CTP-543
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
Time frame: Week 24
Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".
Time frame: Weeks 12, 16, 20, and 24
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
Time frame: Weeks 4, 8, 12, 16, and 20
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).
Time frame: Weeks 12, 16, 20, and 24
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).
Time frame: Weeks 12, 16, 20, and 24
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.
Time frame: Baseline, Weeks 12, and 24
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0 = no eyebrow, 1 = minimal eyebrow, 2 = moderate eyebrow, 3 = normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.
Time frame: Baseline, Weeks 12, and 24
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.
Time frame: Baseline, Weeks 12, and 24
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.
Time frame: Weeks 12, 16, 20, and 24
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.
Time frame: Baseline and Week 24
Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
Time frame: Week 24
Participants were enrolled at study centers in Canada, France, Poland, Spain and the United States from 23 November 2020 to 19 April 2022.
| Milestone | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Started | 140 | 351 | 215 |
| Efficacy population | 140 | 351 | 215 |
| Safety population | 140 | 350 | 215 |
| Completed | 129 | 318 | 199 |
| Not completed | 11 | 33 | 16 |
| Withdrew: Treatment emergent or worsening adverse event | 2 | 8 | 4 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 3 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 | 1 |
| Withdrew: Reason not specified | 4 | 11 | 2 |
| Withdrew: Lost to follow-up | 1 | 10 | 6 |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
| percentage of participants | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24 | 0.8 | 29.6 | 41.5 |
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".
| percentage of responders | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Week 12 | 11.9 | 35.3 | 46.4 |
| Week 16 | 8.3 | 38.2 | 51.5 |
| Week 20 | 6.1 | 37.4 | 54.0 |
| Week 24 | 4.7 | 42.1 | 53.0 |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
| percentage of participants | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Week 4 | 0 | 0.9 | 0 |
| Week 8 | 0 | 3.3 | 6.1 |
| Week 12 | 0.7 | 10.4 | 18.2 |
| Week 16 | 2.3 | 16.5 | 29.6 |
| Week 20 | 0.8 | 24.1 | 37.0 |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).
| percent change | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Relative Change From Baseline at Week 4 | -0.2 ± 5.59 | -2.6 ± 12.79 | -4.0 ± 12.03 |
| Relative Change From Baseline at Week 8 | -2.3 ± 11.41 | -10.9 ± 21.00 | 17.5 ± 27.16 |
| Relative Change From Baseline at Week 12 | -0.6 ± 16.63 | -22.2 ± 29.45 | -31.1 ± 35.53 |
| Relative Change From Baseline at Week 16 | -1.8 ± 21.06 | -30.3 ± 34.20 | -41.2 ± 38.95 |
| Relative Change From Baseline at Week 20 | -1.3 ± 22.14 | -36.0 ± 37.82 | -46.8 ± 41.32 |
| Relative Change From Baseline at Week 24 | -1.5 ± 23.30 | -41.2 ± 39.37 | -50.4 ± 41.52 |
The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).
| percentage of responders | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Week 12 | 3.7 | 36.3 | 43.5 |
| Week 16 | 7.7 | 44.2 | 54.7 |
| Week 20 | 8.4 | 49.1 | 57.1 |
| Week 24 | 9.4 | 53.8 | 59.8 |
The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).
| percentage of responders | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Week 12 | 6.7 | 38.9 | 49.8 |
| Week 16 | 9.0 | 49.1 | 58.3 |
| Week 20 | 10.0 | 50.6 | 60.0 |
| Week 24 | 10.2 | 56.6 | 65.5 |
The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Baseline | 6.5 ± 0.74 | 6.4 ± 0.86 | 6.4 ± 0.76 |
| Change From Baseline at Week 12 | -0.1 ± 0.74 | -1.0 ± 1.38 | -1.4 ± 1.53 |
| Change From Baseline at Week 16 | -0.2 ± 0.99 | -1.3 ± 1.55 | -1.9 ± 1.77 |
| Change From Baseline at Week 20 | -0.1 ± 0.83 | -1.6 ± 1.77 | -2.2 ± 1.92 |
| Change From Baseline at Week 24 | -0.2 ± 0.90 | -1.9 ± 1.89 | -2.4 ± 2.03 |
The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Baseline | 6.5 ± 0.76 | 6.5 ± 0.80 | 6.4 ± 0.86 |
| Change From Baseline at Week 12 | -0.4 ± 1.08 | -1.1 ± 1.64 | -1.4 ± 1.79 |
| Change From Baseline at Week 16 | -0.2 ± 0.78 | -1.5 ± 1.83 | -2.0 ± 1.95 |
| Change From Baseline at Week 20 | -0.3 ± 1.01 | -1.8 ± 2.01 | -2.2 ± 2.07 |
| Change From Baseline at Week 24 | -0.1 ± 0.74 | -1.9 ± 2.05 | -2.4 ± 2.14 |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.
| percentage of participants | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| 75% Relative Reduction: Week 12 | 0 | 8.8 | 17.7 |
| 75% Relative Reduction: Week 24 | 0 | 28.6 | 40.0 |
| 90% Relative Reduction: Week 12 | 0 | 3.4 | 10.0 |
| 90% Relative Reduction: Week 24 | 0 | 19.2 | 32.0 |
BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0 = no eyebrow, 1 = minimal eyebrow, 2 = moderate eyebrow, 3 = normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Baseline | 1.7 ± 2.05 | 1.2 ± 1.77 | 1.4 ± 1.91 |
| Change From Baseline at Week 12 | -0.2 ± 1.38 | 0.8 ± 1.70 | 1.1 ± 2.05 |
| Change From Baseline at Week 24 | -0.2 ± 1.68 | 1.6 ± 1.96 | 1.8 ± 2.17 |
BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Baseline | 1.5 ± 2.12 | 1.4 ± 2.10 | 1.7 ± 2.12 |
| Change From Baseline at Week 12 | -0.1 ± 1.18 | 0.9 ± 1.50 | 1.3 ± 2.08 |
| Change From Baseline at Week 24 | 0.3 ± 1.30 | 1.7 ± 1.99 | 2.0 ± 2.28 |
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Baseline | 4.5 ± 0.86 | 4.5 ± 0.89 | 4.5 ± 0.85 |
| Change From Baseline at Week 12 | -0.6 ± 1.15 | -1.3 ± 1.42 | -1.7 ± 1.36 |
| Change From Baseline at Week 16 | -0.4 ± 1.18 | -1.4 ± 1.44 | -1.8 ± 1.43 |
| Change From Baseline at Week 20 | -0.4 ± 1.14 | -1.4 ± 1.52 | -1.8 ± 1.52 |
| Change From Baseline at Week 24 | -0.3 ± 1.09 | -1.5 ± 1.54 | -1.9 ± 1.64 |
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.
| percentage of participants | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Week 12 | 20.7 | 44.7 | 53.1 |
| Week 16 | 14.3 | 48.1 | 53.9 |
| Week 20 | 13.7 | 47.5 | 57.5 |
| Week 24 | 12.5 | 49.1 | 58.0 |
The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Satisfied Thickness Hair Coverage: Baseline | 4.5 ± 0.79 | 4.6 ± 0.79 | 4.5 ± 0.76 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 12 | -0.4 ± 0.98 | -1.1 ± 1.23 | -1.3 ± 1.17 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 16 | -0.3 ± 1.03 | -1.2 ± 1.28 | -1.5 ± 1.33 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 20 | -0.3 ± 0.98 | -1.3 ± 1.35 | -1.6 ± 1.36 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 24 | -0.2 ± 1.00 | -1.4 ± 1.43 | -1.7 ± 1.45 |
| Satisfied Evenness Hair Coverage: Baseline | 4.6 ± 0.67 | 4.6 ± 0.76 | 4.6 ± 0.68 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 12 | -0.4 ± 0.83 | -1.0 ± 1.19 | -1.3 ± 1.16 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 16 | -0.3 ± 0.84 | -1.1 ± 1.31 | -1.4 ± 1.34 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 20 | -0.3 ± 0.90 | -1.2 ± 1.36 | -1.5 ± 1.40 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 24 | -0.2 ± 0.84 | -1.2 ± 1.41 | -1.6 ± 1.52 |
| How Satisfied With Your Eyebrows: Baseline | 3.8 ± 1.39 | 4.0 ± 1.28 | 3.9 ± 1.35 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 12 | -0.2 ± 0.88 | -1.0 ± 1.20 | -1.1 ± 1.34 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 16 | -0.1 ± 0.90 | -1.1 ± 1.24 | -1.3 ± 1.27 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 20 | -0.2 ± 0.88 | -1.2 ± 1.25 | -1.4 ± 1.32 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 24 | -0.2 ± 0.87 | -1.2 ± 1.26 | -1.4 ± 1.36 |
| How Satisfied With Your Eyelashes: Baseline | 3.7 ± 1.44 | 3.9 ± 1.37 | 3.7 ± 1.44 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 12 | -0.3 ± 0.79 | -0.9 ± 1.21 | -0.9 ± 1.24 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 16 | -0.2 ± 0.97 | -1.0 ± 1.24 | -1.2 ± 1.30 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 20 | -0.3 ± 0.99 | -1.1 ± 1.30 | -1.1 ± 1.33 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 24 | -0.2 ± 0.95 | -1.1 ± 1.37 | -1.2 ± 1.37 |
HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.
| score on a scale | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Anxiety: Baseline | 5.5 ± 3.92 | 6.2 ± 4.06 | 6.0 ± 3.92 |
| Anxiety: Change From Baseline at Week 24 | -0.4 ± 2.98 | -1.0 ± 3.26 | -1.1 ± 3.24 |
| Depression: Baseline | 3.3 ± 3.06 | 3.7 ± 3.31 | 3.6 ± 3.39 |
| Depression: Change From Baseline at Week 24 | -0.7 ± 2.67 | -0.9 ± 2.93 | -1.1 ± 2.88 |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
| percentage of participants | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24 | 0 | 20.8 | 34.5 |
Collected over All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/140 (0%) | 4/140 (2.9%) | 31/140 (22.1%) |
| CTP-543 8 mg BID | 0/351 (0%) | 4/350 (1.1%) | 117/350 (33.4%) |
| CTP-543 12 mg BID | 0/215 (0%) | 1/215 (0.5%) | 75/215 (34.9%) |
| Event | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| AppendicitisInfections and infestations | 1/140 | 1/350 | 1/215 |
| EpilepsyNervous system disorders | 1/140 | 0/350 | 0/215 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/140 | 0/350 | 0/215 |
| Adjustment disorderPsychiatric disorders | 1/140 | 0/350 | 0/215 |
| IleusGastrointestinal disorders | 0/140 | 0/350 | 1/215 |
| COVID-19Infections and infestations | 0/140 | 1/350 | 0/215 |
| MeningitisInfections and infestations | 0/140 | 1/350 | 0/215 |
| Chest painGeneral disorders | 0/140 | 1/350 | 0/215 |
| PyrexiaGeneral disorders | 0/140 | 1/350 | 0/215 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/140 | 1/350 | 0/215 |
| Event | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|---|
| AcneSkin and subcutaneous tissue disorders | 7/140 | 31/350 | 26/215 |
| HeadacheNervous system disorders | 8/140 | 41/350 | 24/215 |
| COVID-19Infections and infestations | 8/140 | 19/350 | 15/215 |
| Upper respiratory tract infectionInfections and infestations | 9/140 | 9/350 | 8/215 |
| Blood creatine phosphokinase (increased)Investigations | 2/140 | 21/350 | 11/215 |
| NasopharyngitisInfections and infestations | 5/140 | 18/350 | 8/215 |
All randomized participants included all participants who were randomized in the study.
| Age, Continuous(years) | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|---|
| Mean | 38.7 ± 13.81 | 38.9 ± 13.32 | 38.2 ± 12.80 | 38.6 ± 13.25 |
| Sex: Female, Male(Participants) | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|---|
| Female | 89 | 217 | 131 | 437 |
| Male | 51 | 134 | 84 | 269 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 11 | 30 | 13 | 54 |
| Not Hispanic or Latino | 119 | 292 | 188 | 599 |
| Unknown or Not Reported | 10 | 29 | 14 | 53 |
| Race/Ethnicity, Customized(Participants) | Placebo | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 2 | 1 | 3 |
| Race — Asian | 10 | 22 | 21 | 53 |
| Race — Black or African American | 16 | 40 | 27 | 83 |
| Race — Native Hawaiian or other Pacific Islander | 1 | 3 | 1 | 5 |
| Race — White | 98 | 241 | 145 | 484 |
| Race — Other | 5 | 17 | 6 | 28 |
| Race — Not reported | 10 | 26 | 14 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Apr 2022, 16 months.
Results were first posted in May 2023, 1 year after primary completion.
Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib